Kedrion Biopharma is a global player in the biopharmaceutical sector dedicated to collecting and fractionating plasma to produce and distribute plasma-derived therapies for rare, ultra-rare, and debilitating conditions like Coagulation and Neurological Disorders, Immunodeficiencies, and Rh sensitization. With a portfolio of 38 products, Kedrion is the world’s fifth largest player in the plasma-derived space. At Kedrion, science meets humanity, ensuring that innovation and care go hand in hand. Partnering with the medical-scientific community, institutions, patient advocacy groups, and research bodies, Kedrion is committed to foster innovation and improve patient’s access to care.